Status: Recruiting
A Trial to Assess Safety, Tolerability, and Pharmacokinetics of AN01 Inhalation Powder in Healthy Participants
AN01 is a selective small-molecule dual inhibitor of phosphodiesterase 3 and 4 (PDE3/4). As a potential new therapy for COPD, AN01 is expected to serve either as a monotherapy for COPD or as adjunctive therapy to current inhaled standard treatments, potentially generating synergistic complementary effects in patients requiring additional therapeutic options. The primary objective of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple doses of AN01 in healthy participants.
Participants needed: 24
Trial details
Phase: Phase 1Age: 18-60Biological sex: AllType: InterventionalSponsor: AirNexis Therapeutics, Inc.Updated: May 28, 2026Locations: 1
Eligibility criteria
Healthy adults ≥18 and ≤60 years (inclusive). [+5]
History of clinically significant (as per Investigator's judgment) upper respira... [+7]